Musa HA, Osman MAM, Abdelaziz YH, Mohamed S, Ibrahim-Saeed M

Language: English
References: 22
Page: 80-84
PDF size: 292.57 Kb.

ABSTRACT

Proteus species are found in the human intestinal tract as part of normal flora. Proteus species are also found in multiple environmental habitats, including long-term care facilities and hospitals, and can cause both community and nosocomial infections. For a long time Proteus was known to be susceptible to beta-lactam antibiotics but nowadays they become resistant. The aim of this study was to detect the Extended-spectrum beta-lactamase (ESBL) TEM and CTX-M genes in 90 Proteus species isolated from urine and wound swabs, obtained from different hospitals in Khartoum state, Sudan, from January to August 2018. Antimicrobial sensitivity was carried out using the following set of antibiotics: amoxiclav, ceftazidime, gentamicin, meropenem, cefotaxime, ciprofloxacin, amoxicillin, ceftriaxone and cotrimoxazole. ESBL producing strains were detected by double disc diffusion synergy test and the resistance genes TEM and CTX-M were detected by Polymerase Chain Reaction (PCR). Antibiotic resistance was found: amoxicillin 40%, ceftazidime 25.6%, ceftriaxone 23.3%, gentamicin 22.2%, cotrimoxazole 21.1%, and cefotaxime 18.9%. Most of the isolates were sensitive to meropenem 92.2% and ciprofloxacin 86.7%. In double-disk diffusion synergy test, 20 isolates (22.2%) were found to be positive for ESBL. The PCR demonstrated that TEM gene was present in 18 isolates (90%). It was present alone in 11 isolates (55%) and in combination with CTX-M gene in seven isolates (35%). The percentage of ESBL producing strains of Proteus was 23.5%. This percentage is a bit lower than in previous studies in Sudan. In conclusion; it seems that the CTX-M gene is emerging among Proteus species in Sudan.

REFERENCES

1. Cloherty JP. Maternal conditions that affect the fetus: Diabetes mellitus. In Cloherty JP, Stark. AR, editors. Manual of neonatal care 4th edition, Philadelphia: Lippincott-Raven Publishers; 1998. p.15-9.

2. Calil R, Marba ST, von Nowakonski A, Tresoldi AT. Reduction in colonization and nosocomial infection by multiresistant bacteria in a neonatal unit after institution of educational measures and restriction in the use of cephalosporins. Am J Infect Control. 2001;29(3):133-8.

3. Khan MK, Thukral SS, Gaind R. Evaluation of a modified double-disc synergy test for detection of extended spectrum β-lactamases in AMPC β-lactamase-producing Proteus mirabilis. Indian J Med Microbiol. 2008;26(1)58-61.

4. Al-Muharrmi Z, Rafay A, Balkhair A, Jabri AA. Antibiotic combination as empirical therapy for extended spectrum Beta-lactamase. Oman Med J. 2008;23(2):78-81.

5. Nathisuwan S, Burgess DS, Lewis JS. Extended‐spectrum β‐lactamases: epidemiology, detection, and treatment. Pharmacotherapy 2001;21(8):920-8.

6. Bali EB, Acik L, Sultan N. Phenotypic and molecular characterization of SHV, TEM, CTX-M and extended-spectrum beta-lactamase produced by Escherichia coli, Acinobacter baumannii and Klebsiella isolates in a Turkish hospital. Afr J Microbiol Res. 2010;4(8):650-4.

7. Seyedjavadi SS, Goudarzi M, Sabzehali F. Relation between blaTEM, blaSHV and blaCTX-M genes and acute urinary tract infections. J Acute Dis. 2016;5(1):71-6.

8. Coyle MB. Manual of antimicrobial susceptibility testing. Washington DC: American Society for Microbiology; 2005.

9. Mordi RM, Momoh MI. Incidence of Proteus species in wound infections and their sensitivity pattern in the University of Benin Teaching Hospital. Afr J Biotechnol. 2009;8(5):725-30.

10. Jones RN, Baquero F, Privitera G, Inoue M, Wiedemann B. Inducible β‐lactamase‐mediated resistance to third‐generation cephalosporins. Clin Microbiol Infect. 1997;3(Suppl 1):S7-S20.

11. Gualerzi CO, Brandi L, Fabbretti A, Pon CL, editors. Antibiotics: targets, mechanisms and resistance. Weinheim, Germany: Wiley-VCH; 2014.

12. Roe BA, Crabtree JS, Khan AS. DNA isolation and sequencing. New York: Wiley-Blackwell; 1996.

13. Ahmed OI, El-Hady SA, Ahmed TM, Ahmed IZ. Detection of bla SHV and bla CTX-M genes in ESBL producing Klebsiella pneumoniae isolated from Egyptian patients with suspected nosocomial infections. Egypt J Med Hum Genet. 2013;14(3):277-83.

14. Hassan RM, Hammad MN. Prevalence and Antimicrobial Susceptibility Pattern of Extended Spectrum β-Lactamases Producing Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis in Khartoum Sudan. Am J Res Commun. 2016;4(8):60-6.

15. Ahmed OB, Omar AO, Asghar AH, El Hassan MM. Increasing prevalence of ESBL-producing Enterobacteriaceae in Sudan community patients with UTIs. Egypt Acad J Biolog Sci. 2013;5(1):17-24.

16. Bauernfeind A, Holley M, Jungwirth R, Mangold P, Röhnisch T, Schweighart S, et al. A new plasmidic cefotaximase from patients infected with Salmonella typhimurium. Infection. 1992;20(3):158-63.

17. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty Informational Supplement. CLSI document M100-S20. Wayne, PA: CLSI; 2010.

18. Fazeli H, Dolatabadi RK, Taraghian A, Isfahani BN, Nasr Nasr B, Moghim SH, et al. Carbapenem Resistance Pattern of Multiple Drug-Resistantand Extended-Spectrum Beta-Lactamase-Positive Klebsiella pneumonia in Isfahan. Int J Enteric Pathog. 2014;2(4):e21495. Doi:10.17795/ijep21495.

19. Miriagou V, Cornaglia G, Edelstein M, Galani I, Giske CG, Gniadkowski M, et al. Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clin Microbiol Infect. 2010;16(2):112-22.

20. Endimiani A, Luzzaro F, Brigante G, Perilli M, Lombardi G, Amicosante G, et al. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum β-lactamases. Antimicrob Agents Chemother. 2005;49(7):2598-605.

21. Hindi AK. Phenotyping and Molecular Characterization of Proteus vulgaris Isolated from Patients with Urinary Tract Infections [dissertation]. Babylon, Irak: College of Science, University of Babylon; 2014.

22. Caubey M, Suchitra M. Occurrence of TEM, SHV and CTX-M β Lactamases in Clinical Isolates of Proteus Species in a Tertiary Care Center. Infect Disord Drug Targets. 2018;18(1):68-71.